BAC Water 10mL
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.

SKU: PW-001 • Batch: PW-260301
Triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial at 99.4% HPLC purity. Independently tested with a full COA on every batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Dispatched next business day (orders before 11PM AEST)
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.
Purity independently verified at a leading Australian university via HPLC & mass spectrometry.
Retatrutide (LY3437943) is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Supplied as a lyophilised powder at 99.4% HPLC purity with full Certificate of Analysis (COA) documentation.
Synthesis happens under one roof at our GMP-compliant Australian facility, so chain-of-custody documentation runs unbroken from raw material to the vial that ships. An accredited third-party lab — not us — independently confirms HPLC purity, mass spectrometry identity, LAL endotoxin levels (<1.0 EU/mg), and sterility on every batch before dispatch.
Research has explored Retatrutide's simultaneous activation of three complementary receptor pathways for effects on energy homeostasis, body composition, and metabolic function, producing distinct profiles compared to single (GLP-1) or dual (GLP-1/GIP) agonists studied in the literature.
Retatrutide (LY3437943) is a triple GLP-1/GIP/Glucagon receptor agonist investigated in preclinical and clinical research for its effects on metabolic function, body weight regulation, and energy homeostasis. All use is strictly for in-vitro laboratory research only.
Our Retatrutide 10mg is independently verified at 99.4% HPLC purity. Each batch is tested by an accredited third-party laboratory and comes with a full Certificate of Analysis (COA).
Lyophilised Retatrutide should be stored at −20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Add bacteriostatic water (BAC water) slowly to the vial at a 1–2mL volume. Gently swirl; do not shake. Allow the lyophilised powder to dissolve completely before use in research protocols.
Retatrutide can be legally purchased in Australia for legitimate in-vitro laboratory and research purposes. Scheduling under the Poisons Standard attaches to the substance and changes over time, so "sold for research use" isn't itself an exemption — verify current status against the TGA's Poisons Standard rather than assuming it's unscheduled. It is not approved for human consumption or therapeutic use.
Current batch: PW-260301. The COA for this batch is available on our COA Library page, including full HPLC chromatogram, purity %, mass spectrometry data, and endotoxin results.
Yes. Every batch of Retatrutide ships with a downloadable COA including HPLC purity percentage, mass spectrometry identity confirmation, sterility results, and LAL endotoxin assay data.
Semaglutide is a single GLP-1 receptor agonist, while Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In research settings, Retatrutide's multi-receptor activity produces distinct metabolic effects compared to single-target compounds.
Yes. Peptide Labs ships Retatrutide nationwide across Australia via Australia Post with tracking. Orders placed before 11PM AEST are dispatched the next business day.
Bacteriostatic water (BAC water) is the recommended reconstitution solvent for Retatrutide. We stock pharmaceutical-grade BAC water 10mL in our Supplies category.
Retatrutide 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to Retatrutide. Provided for research context — not medical advice.
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. · Biomolecules · 2025
PMID: 40563436
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · The New England journal of medicine · 2023
PMID: 37366315
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Giblin K, Kaplan LM, Somers VK, et al. · Diabetes, obesity & metabolism · 2026
PMID: 41090431
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, et al. · Lancet (London, England) · 2023
PMID: 37385280
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.